专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 当视角进一步聚焦至中国经济中心上海时，该地区的医药生物行业CFO薪酬溢价效应更为明显。统计范 围内的39家上海医药生物企业，CFO薪酬总额达4442.62万元，其平均年薪跃升至约113.91万元（中位数 102.20万元）。 这一数字相比全市场CFO平均薪酬高出39.8%（约32.43万元），凸显了上海作为高运营成本、高人才竞 争核心区域，叠加医药生物这一高附加值行业的强力薪酬溢价。 在上海地区医药生物行业上市公司CFO薪酬榜单中，奥浦迈（股票代码：688293.SH）的首席财务官倪 亮萍女士以140.29万元的年薪位列第九位。其2023年年薪为141.60万元，2024年略有下降，变化额 为-1.31万元，变化率为-0.93%。 倪亮萍女士在财务管理领域拥有丰富经验。公开资料显示，倪亮萍出生于1984年，毕业于上海财经大 学，目前为中欧国际商学院EMBA在读。她持有英国皇家特许管理会计师证书（CIMA）和全球特许管 理会计师证书（CGMA）。 在加入奥浦迈之前，倪亮萍女士的职业履历主要包括：2008年至2018年间历 ...

聚焦行业层面，医药生物行业（申万一级）进入统计的395家上市公司CFO平均年薪约为91.97万元（中位数约74.23万元，合计金额3.63亿元），这表明该行业CFO的薪酬水平已显著高于全市 当我们进一步将目光锁定核心区域上海，其医药生物行业的CFO薪酬水平跃升趋势更为明显。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 新浪财经《2024年度A股CFO数据报告》最新出炉，揭示了上市公司财务总监群体的薪酬格局。数据显示，2024年A股上市公司财务总监（CFO）薪酬总额达42.70亿元，平均年薪为81.48万元 区域溢价显著：上海医药生物CFO薪酬高地 分析上海医药CFO薪酬登顶现象，我们认为，这不仅是资深财务高管价值在优质企业的体现，更是上海作为核心城市吸引和留住顶尖金融管理人才的典型缩影，生动诠释了报告所揭示的区域与行 声明：本文由AI大模型生成。市场有风险，投资需谨慎。数据来源于choice，截止2024年末任期不满1年的不参与统计。 这一现象清晰地表明，尽管年度薪酬出现回调，但上海医药首席财务官这一核心岗位本身的价值评估、职责份量以及其在区域人才市场中的标杆地 ...

金融界消息 截至2025年8月1日收盘，上海医药（601607）报收于19.3元，上涨1.37%，换手率0.66%， 成交量18.53万手，成交金额3.58亿元。 资金流向方面，今日主力资金净流入1576.03万元，占比成交额4.4%。其中，超大单净流入2346.78万 元、占成交额6.55%，大单净流出770.75万元、占成交额2.15%，中单净流出流出1673.94万元、占成交 额4.67%，小单净流入97.91万元、占成交额0.27%。 上海医药最新一期业绩显示，截至2025一季报，公司营业总收入707.63亿元、同比增长0.87%，归属净 利润13.33亿元，同比减少13.56%，扣非净利润12.63亿元，同比减少8.10%，流动比率1.355、速动比率 1.066、资产负债率62.23%。 天眼查商业履历信息显示，上海医药集团股份有限公司，成立于1994年，位于上海市，是一家以从事零 售业为主的企业。企业注册资本370278.8059万人民币，实缴资本268891.0538万人民币。公司法定代表 人为杨秋华。 通过天眼查大数据分析，上海医药集团股份有限公司共对外投资了88家企业，参与招投标项目167 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海醫藥集團股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02607 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | FF301 | 2. 股份分類 | 普通股 | 股份類別 | A ...

Group 1 - Shanghai Pharmaceuticals Holdings Co., Ltd. ranked 407th in the 2025 Fortune Global 500 list, marking its sixth consecutive year on the list [2] - In the 2025 Fortune China 500 list, Shanghai Pharmaceuticals ranked 98th, second among pharmaceutical companies [2] - The company achieved a revenue of 275.25 billion yuan in 2024, a year-on-year increase of 5.75%, and a net profit of 4.55 billion yuan, up 20.82% year-on-year [2] Group 2 - In the pharmaceutical manufacturing sector, Shanghai Pharmaceuticals operates production bases in 12 provinces and cities in China and overseas, producing around 800 drug specifications [2] - The company has 54 new drug pipelines that have received clinical trial application acceptance as of the end of 2024 [2] - The company has 44 products with industrial sales exceeding 100 million yuan, including 2 products exceeding 1 billion yuan [2] Group 3 - In the pharmaceutical commercial sector, Shanghai Pharmaceuticals' distribution network covers all 31 provinces, municipalities, and autonomous regions in China [3] - The company aims to strengthen commercial innovation and deepen the CSO model, collaborating with multinational pharmaceutical companies for innovative drug promotion [3] - The commercial sales revenue is expected to exceed 250 billion yuan for the first time in 2024 [3] Group 4 - Shanghai Pharmaceuticals is actively expanding into international markets, using Hong Kong as a base to register and launch traditional Chinese medicine [3] - The company is accelerating its expansion into Southeast Asia and the Middle East, enhancing the global influence of Chinese pharmaceutical brands [3] Group 5 - Looking ahead, Shanghai Pharmaceuticals aims to strengthen its role as a "chain leader" and enhance its core competitiveness, striving to become a world-class enterprise [4] - The company plans to implement a development system focused on "solidifying the foundation, strengthening the core, and innovating breakthroughs" [4]

Core Insights - Shanghai Pharmaceuticals Holding Co., Ltd. ranked 407th in the 2025 Fortune Global 500 list, marking its sixth consecutive year on the list, reflecting its sustainable development and enhanced core competitiveness [2] - In the 2025 Fortune China 500 list, the company ranked 98th, second among pharmaceutical companies, showcasing its strong position in the industry [4] Financial Performance - For the full year of 2024, the company achieved a revenue of RMB 275.25 billion, a year-on-year increase of 5.75%, and a net profit attributable to shareholders of RMB 4.55 billion, up 20.82% year-on-year [4] - In the first half of 2025, the company expects to achieve a net profit attributable to shareholders of approximately RMB 4.45 billion, representing a year-on-year growth of about 52% [4] Industrial and Commercial Operations - The pharmaceutical manufacturing segment operates production bases in 12 provinces in China and overseas, producing around 800 drug specifications and over 30 dosage forms, with multiple products certified by WHO, FDA, and EU [5] - The commercial segment has a distribution network covering all 31 provinces in China, with commercial sales revenue exceeding RMB 250 billion for the first time in 2024, driven by network expansion and management integration [5] Research and Development - The company has 54 new drug candidates in clinical trial stages, including 40 innovative drugs and 14 modified new drugs, with 44 products generating over RMB 100 million in sales, including 2 products exceeding RMB 1 billion [5] International Expansion - Shanghai Pharmaceuticals is actively expanding into international markets, using Hong Kong as a base to register and launch traditional Chinese medicine, while also targeting Southeast Asia and the Middle East to enhance the global influence of Chinese pharmaceutical brands [5] Future Outlook - The company aims to strengthen its role as a "chain leader" enterprise, focusing on solidifying its foundation, enhancing core capabilities, and driving innovation, with a goal of becoming a world-class enterprise and contributing to global health [5]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for clinical trials of its B019 injection for the treatment of refractory systemic lupus erythematosus, marking a significant step in its drug development process [1][2]. Group 1: Project Basic Information - The drug B019 is a chimeric antigen receptor (CAR) T-cell injection targeting CD19 and CD22, designed for refractory systemic lupus erythematosus [2]. - The clinical trial application for B019 was accepted on April 29, 2025, under registration number CXSL2500344, and the approval notice number is 2025LP01884 [1][2]. Group 2: R&D and Registration Status - B019 has previously received approvals for clinical trials targeting relapsed or refractory acute B-cell leukemia and relapsed or refractory B-cell non-Hodgkin lymphoma, with applications approved in October 2023 and December 2024, respectively [2]. - The project is developed independently by Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Biotherapy, which holds complete intellectual property rights [2]. - As of the announcement date, approximately 149,000 RMB has been invested in the R&D of the new indication [2]. Group 3: Market Situation - As of the announcement date, there are no other drugs on the market targeting the same indication with the same mechanism [3]. Group 4: Impact on the Company - The approval for B019's new indication does not have a significant immediate impact on the company's operations, but the company will actively promote the project in accordance with national regulations and fulfill information disclosure obligations regarding future progress [4].

证券代码：601607 证券简称：上海医药 编号：临2025-076 上海医药集团股份有限公司 关于 B019 新适应症获得临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海医药集团生物治疗技术有限公司（以下简称"上药生物治疗"）自主研发 的"B019"（以下简称"B019 注射液"或"该项目"）收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的《药物临床试验批准通知书》，同意其开 展难治性系统性红斑狼疮（以下简称"新适应症"）的临床试验。现将有关情况 公告如下： 一、该项目基本信息 药物名称：靶向 CD19 和 CD22 的嵌合抗原受体自体 T 细胞注射液 剂型：注射剂 申请事项：境内生产药品注册临床试验 受理号：CXSL2500344 通知书编号：2025LP01884 上海医药集团股份有限公司 二、该项目研发及注册情况 B019 注射液是靶向 CD19 和 CD22 的嵌合抗原受体自体 T 细胞注射液，拟用 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), received a Supplementary Application Approval Notice from the National Medical Products Administration for its Salbutamol Sulfate Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Salbutamol Sulfate Injection is primarily used for treating bronchial asthma or wheezing bronchitis and other respiratory diseases associated with bronchospasm [1]

格隆汇7月29日丨上海医药(601607.SH)公布，下属上海医药集团生物治疗技术有限公司（简称"上药生 物治疗"）自主研发的"B019"（简称"B019注射液"或"该项目"）收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，同意其开展难治性系统性红斑狼疮的临床试验。 ...